Genomic Testing is designed to help identify DNA alterations and is done on cancerous tissue in order to provide information with it. It evaluates the genes in a sample of diseased tissue from a cancer patient.
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
COVID-19 is a severe disease that has caused >1 million deaths in under one year. As this disease is novel, the molecular and cellular underpinnings of the progressive tissue injury are p...
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched S...
Since late 2020, several prominent SARS-CoV-2 variants of concern have emerged harboring specific mutations which increase viral transmissibility (e.g., lineage B.1.1.7), and which appear to...
Precise diagnosis of neurodevelopmental disorders (NDDs), which often have genetic causes, is a challenging and important problem. Here we describe the results of a recent pilot study using...
Several SARS-CoV-2 variants are circulating globally. The most prominent variants of concern, including the B.1.1.7, B.1.351 and B1.1.28 lineages, not only carry a constellation of genetic m...
Even as COVID-19 vaccines are being deployed around the world, the clinical laboratory will continue to play a major role this year helping to control the pandemic by diagnosing new infectio...
At UC Davis we have implemented rapid, inexpensive, high throughput testing for SARS-Cov-2 using technology repurposed from the agricultural biotechnology sector. As part of Healthy Davis To...
November 13, 2020 5:00 PM PST | November 14, 2020 9:00 AM SGT
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
What if your lab could perform exome sequencing with the same sensitivity and efficiency of targeted sequencing? The new integrated QIAseq Human Exome TR Insights solution from QIAGEN delive...
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
To identify genetic variants in archival human samples, researchers need a powerful NGS platform that can accommodate input DNA and RNA that is often low quality and/or low quantity. This ch...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
COVID-19 is a severe disease that has caused >1 million deaths in under one year. As this disease is novel, the molecular and cellular underpinnings of the progressive tissue injury are p...
Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched S...
Since late 2020, several prominent SARS-CoV-2 variants of concern have emerged harboring specific mutations which increase viral transmissibility (e.g., lineage B.1.1.7), and which appear to...
Precise diagnosis of neurodevelopmental disorders (NDDs), which often have genetic causes, is a challenging and important problem. Here we describe the results of a recent pilot study using...
Several SARS-CoV-2 variants are circulating globally. The most prominent variants of concern, including the B.1.1.7, B.1.351 and B1.1.28 lineages, not only carry a constellation of genetic m...
Even as COVID-19 vaccines are being deployed around the world, the clinical laboratory will continue to play a major role this year helping to control the pandemic by diagnosing new infectio...
At UC Davis we have implemented rapid, inexpensive, high throughput testing for SARS-Cov-2 using technology repurposed from the agricultural biotechnology sector. As part of Healthy Davis To...
November 13, 2020 5:00 PM PST | November 14, 2020 9:00 AM SGT
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
What if your lab could perform exome sequencing with the same sensitivity and efficiency of targeted sequencing? The new integrated QIAseq Human Exome TR Insights solution from QIAGEN delive...
Ensuring that clinical tests are not affected by tumor heterogeneity requires a sampling methodology that captures the genomic, proteomic, and cellular diversity of entire solid tumors. Howe...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
To identify genetic variants in archival human samples, researchers need a powerful NGS platform that can accommodate input DNA and RNA that is often low quality and/or low quantity. This ch...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Comprehensive genomic profiling in clinical research studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies...
Comprehensive genomic profiling in clinical studies helps to detect clinically relevant cancer driver mutations using low amount of tumor tissues within several days. Recent studies have sho...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
The continued rapid expansion of immunotherapies, including both in vivo and ex vivo therapeutics, has driven the development and adoption of novel tools to study, asses and understand these...
Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer...
Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and mor...
Follow
